Signal Chooses Acquisition By Celgene Over Initial Public Offering
Executive Summary
Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.
You may also be interested in...
Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force
Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.
Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force
Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.
Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.